Impact startupHealthSeries C+

NewLimit

NewLimit is a longevity startup based in South San Francisco. It aims to extend human healthspan by reversing the aging process at the cellular level. The company plans its first clinical trial, of a liver medicine.

newlimit.com

Co-founder and CEO

Jacob Kimmel

Founders

Brian Armstrong, Blake Byers, Jacob Kimmel

Founded

2021

Who it reaches

Its first planned clinical trial is for a liver medicine.

Key facts

Founded: 2021source
Headquarters: South San Franciscosource
Series C: $435 million, led by Founders Fundsource
Valuation: around $3.1 billion, according to co-founder and CEO Jacob Kimmelsource
First clinical trial: first trial targets the liver and is to begin next yearsource

WYDE coverage of NewLimit

Healthcare

Life Biosciences Doses the First Patient as Cellular Rejuvenation Reaches Human Trials

Jul 14, 2026 · 2 min read

Crypto & DeFi

Coinbase CEO's Longevity Startup NewLimit Raises $435 Million at $3.1 Billion Valuation

Jun 23, 2026 · 2 min read

Sources

Track the institutions that move money.

Data-driven coverage every Friday.